KMT2C and myelodysplastic syndrome: KMT2C mutations have been detected in a variety of tumors, including hepatocellular carcinoma (30), breast cancer (31), colon cancer (32), bladder cancer (33), myelodysplastic syndromes and acute myeloid leukemia (AML) (34).